Novavax, Inc. (NVAX) Trading Up -3.3% on Insider Buying Activity

Novavax, Inc. (NASDAQ:NVAX) shares were up 3.3% on Tuesday after an insider bought additional shares in the company. The company traded as high as $1.23 and last traded at $1.18. Approximately 2,639,937 shares changed hands during mid-day trading, a decline of 56% from the average daily volume of 5,956,744 shares. The stock had previously closed at $1.22.

Specifically, Director James F. Young sold 175,000 shares of the stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $1.06, for a total value of $185,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Stanley C. Erck bought 100,000 shares of Novavax stock in a transaction dated Thursday, November 9th. The stock was acquired at an average price of $1.13 per share, with a total value of $113,000.00. Following the acquisition, the insider now directly owns 228,279 shares of the company’s stock, valued at $257,955.27. The disclosure for this purchase can be found here. Company insiders own 4.00% of the company’s stock.

A number of analysts have recently issued reports on NVAX shares. Citigroup Inc. upgraded Novavax from a “neutral” rating to a “buy” rating and set a $2.00 target price for the company in a report on Tuesday, October 31st. Zacks Investment Research upgraded Novavax from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a report on Wednesday, August 16th. Ladenburg Thalmann Financial Services upgraded Novavax from a “neutral” rating to a “buy” rating and set a $1.60 target price for the company in a report on Wednesday, August 9th. Piper Jaffray Companies restated a “hold” rating and issued a $1.50 target price on shares of Novavax in a report on Wednesday, July 26th. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $2.00 target price on shares of Novavax in a report on Friday, July 21st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company’s stock. Novavax presently has a consensus rating of “Hold” and a consensus price target of $3.12.

The company has a current ratio of 3.31, a quick ratio of 3.31 and a debt-to-equity ratio of -4.28.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.01. Novavax had a negative return on equity of 787.38% and a negative net margin of 726.35%. The business had revenue of $8.35 million during the quarter, compared to analyst estimates of $6.42 million. During the same period last year, the company earned ($0.24) earnings per share. Novavax’s quarterly revenue was up 158.5% compared to the same quarter last year. analysts expect that Novavax, Inc. will post -0.61 EPS for the current fiscal year.

Several large investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of Novavax by 4.5% during the first quarter. Vanguard Group Inc. now owns 21,681,318 shares of the biopharmaceutical company’s stock worth $27,752,000 after acquiring an additional 938,581 shares in the last quarter. JPMorgan Chase & Co. increased its position in Novavax by 40.1% during the second quarter. JPMorgan Chase & Co. now owns 5,196,508 shares of the biopharmaceutical company’s stock worth $5,976,000 after buying an additional 1,488,403 shares during the last quarter. Northern Trust Corp increased its position in Novavax by 2.8% during the second quarter. Northern Trust Corp now owns 3,376,714 shares of the biopharmaceutical company’s stock worth $3,883,000 after buying an additional 92,854 shares during the last quarter. Geode Capital Management LLC increased its position in Novavax by 18.3% during the first quarter. Geode Capital Management LLC now owns 2,400,960 shares of the biopharmaceutical company’s stock worth $3,073,000 after buying an additional 371,295 shares during the last quarter. Finally, GSA Capital Partners LLP increased its position in Novavax by 38.7% during the second quarter. GSA Capital Partners LLP now owns 1,690,153 shares of the biopharmaceutical company’s stock worth $1,944,000 after buying an additional 471,347 shares during the last quarter. Institutional investors and hedge funds own 38.87% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://sportsperspectives.com/2017/11/14/novavax-inc-nvax-trading-up-3-3-on-insider-buying-activity.html.

About Novavax

Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.

Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply